MacroGenics MGNX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
MacroGenics (MGNX) Business Model and Operations Summary
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Key Insights
MacroGenics (MGNX) Core Market Data and Business Metrics
Latest Closing Price
$1.22Market Cap
$76.65 MillionPrice-Earnings Ratio
-1.14Total Outstanding Shares
63.09 Million SharesTotal Employees
341Dividend
No dividendIPO Date
October 10, 2013SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
9704 Medical Center Drive, Rockville, MD, 20850
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $81.88 Million |
| Net Cash Flow From Operating Activities, Continuing | $-68.37 Million |
| Net Cash Flow From Operating Activities | $-68.37 Million |
| Net Cash Flow From Financing Activities | $960,000 |
| Net Cash Flow From Investing Activities | $149.30 Million |
| Net Cash Flow From Investing Activities, Continuing | $149.30 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Other Operating Expenses | $82.50 Million |
| Basic Average Shares | $62.62 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Research and Development | $177.19 Million |
| Cost Of Revenue | $847,000 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-66.96 Million |
| Other Comprehensive Income/Loss | $-66.96 Million |
| Comprehensive Income/Loss | $-66.96 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $55.53 Million |
| Other Current Liabilities | $50.52 Million |
| Other Non-current Assets | $26.07 Million |
| Other Current Assets | $205.98 Million |
| Prepaid Expenses | $11.51 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||